NCT03054766

Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

The Randomized Double-blind Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Beijing Hospital · Other Government
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

To investigate the efficacy of laser photocoagulation combined with ranibizumab intravitreal injection in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in long term.

Detailed description

To investigate the efficacy of ranibizumab intravitreal injections-driven by achieving vision acuity stabilization compared to combination with laser photocoagulation in Chinese patients with visual impairment in ME due to BRVO. The result of the trial will be used to support new therapy in the BRVO in China.

Conditions

• Branch Retinal Vein Occlusion
• Ranibizumab
• Laser Photocoagulation

Interventions

Type	Name	Description
PROCEDURE	Ranibizumab combined macular laser	subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
DRUG	Ranibizumab	all subjections received 3+PRN ranibizumab injections by BCVA stabilization

Timeline

• Start date: 2017-02-14
• Primary completion: 2018-02-01
• Completion: 2019-01-28
• First posted: 2017-02-16
• Last updated: 2022-12-28

Locations

1 site across 1 country: China